{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T20:12:23Z","timestamp":1779826343739,"version":"3.53.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematological malignancies but is associated with significant immune-mediated toxicities, particularly cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, driven by an exaggerated inflammatory response involving cytokines such as interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha. These processes contribute to endothelial dysfunction and a spectrum of cardiovascular complications, including hypotension, arrhythmias, myocardial dysfunction, and heart failure. The underlying pathophysiology involves complex interactions between immune activation and vascular injury, often progressing rapidly and necessitating early recognition. Contemporary management is shifting from reactive treatment to proactive strategies, emphasizing early risk stratification using clinical parameters, biomarkers, and imaging, alongside timely intervention with cytokine-directed therapies such as IL-6 and IL-1 inhibitors. Integration of cardiology within multidisciplinary care teams is essential for optimizing outcomes through tailored monitoring and management of cardiovascular complications. As chimeric antigen receptor T-cell therapy expands to broader and higher-risk populations, including those with pre-existing cardiovascular disease, a structured cardio-oncology approach and further prospective research are critical to improving safety and long-term outcomes.<\/jats:p>","DOI":"10.1097\/crd.0000000000001327","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T20:00:09Z","timestamp":1779825609000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pre-emptive and Prophylactic Strategies to Prevent Cardiovascular and Neurotoxicity in Chimeric Antigen Receptor T-Cell Therapy: The Role of Tocilizumab, Anakinra, and Cytokine-Targeted Interventions"],"prefix":"10.1097","author":[{"given":"Jatin","family":"Thukral","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninaad","family":"Sindhwani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyush","family":"Moudgil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Singla","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushi","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya Kaushal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamilton Medical Center, Dalton, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Thukral","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, Pt. Deendayal Upadhyaya National Institute for Persons With Physical Disabilities, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth Pravin","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management.","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome.","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy.","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS.","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"R8-20260526","doi-asserted-by":"crossref","first-page":"623610","DOI":"10.3389\/fimmu.2021.623610","article-title":"Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation.","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/cancers17172876","article-title":"Endothelial injury following CAR-T cell immunotherapy for hematological malignancies.","volume":"17","author":"Demosthenous","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/ijms25010644","article-title":"The mechanisms of altered blood-brain barrier permeability in CD19 CAR T-cell recipients.","volume":"25","author":"Pinto","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review.","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular toxicities of CAR T-cell therapy.","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study.","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T).","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R17-20260526","first-page":"52","article-title":"Cardiac adverse events after chimeric antigen receptor (CAR) T cell therapies: an updated systematic review and meta-analysis.","volume":"10","author":"Maleki","year":"2024","journal-title":"Cardiooncology"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjh.19497","article-title":"Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.","volume":"205","author":"Shouval","year":"2024","journal-title":"Br J Haematol"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"suac121.116","DOI":"10.1093\/eurheartjsupp\/suac121.116","article-title":"Takotsubo syndrome after CAR-T cell infusion.","volume":"24","author":"Bastianoni","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41409-022-01562-4","article-title":"Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy.","volume":"57","author":"Feng","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy.","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).","volume":"10","author":"Wehrli","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy.","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies.","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"R26-20260526","doi-asserted-by":"crossref","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer.","volume":"385","author":"Palaskas","year":"2024","journal-title":"BMJ"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R28-20260526","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome.","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R29-20260526","first-page":"e498","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome.","volume":"19","author":"Le","year":"2018","journal-title":"Lancet Oncol"},{"key":"R30-20260526","first-page":"2065","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"R31-20260526","first-page":"2863","article-title":"Immune checkpoint inhibitor-associated myocarditis.","volume":"138","author":"Ganatra","year":"2018","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T20:00:13Z","timestamp":1779825613000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001327","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}